News
In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback